https://www.marketscreener.com/quote/stock/ECKERT-ZIEGLER-SE-436039/news/First-CNS-Lymphoma-Patient-Dosed-in-Phase-I-II-PTT101-Study-with-Yttrium-90Y-Anditixafortide-Pent-45419393/?utm_source=telegram&utm_medium=social&utm_campaign=share